Last reviewed · How we verify
Elimite™ Cream (permethrin) 5%
Permethrin is a synthetic pyrethroid insecticide that disrupts sodium channel function in the nervous system of parasites, causing paralysis and death.
Permethrin is a synthetic pyrethroid insecticide that disrupts sodium channel function in the nervous system of parasites, causing paralysis and death. Used for Scabies (Sarcoptes scabiei infestation), Head lice (Pediculus humanus capitis infestation).
At a glance
| Generic name | Elimite™ Cream (permethrin) 5% |
|---|---|
| Also known as | Elimite™ Cream |
| Sponsor | Encube Ethicals Pvt. Ltd. |
| Drug class | Pyrethroid insecticide |
| Target | Voltage-gated sodium channels |
| Modality | Small molecule |
| Therapeutic area | Dermatology / Parasitology |
| Phase | Phase 3 |
Mechanism of action
Permethrin acts as a neurotoxin by binding to voltage-gated sodium channels in arthropod nerve and muscle cells, preventing normal repolarization and leading to sustained depolarization. This results in paralysis and death of the parasite. The drug is selectively toxic to arthropods due to their greater sensitivity compared to mammals, which have different sodium channel kinetics and metabolism.
Approved indications
- Scabies (Sarcoptes scabiei infestation)
- Head lice (Pediculus humanus capitis infestation)
Common side effects
- Pruritus
- Erythema
- Burning sensation
- Tingling or numbness
- Rash
Key clinical trials
- A Bioequivalence Study With Clinical Endpoints to Evaluate the Safety and Therapeutic Equivalence of Permethrin Cream 5% & Elimite™ in Subjects With Scabies (PHASE3)
- Bio-equivalence Study Comparing Permethrin Cream, 5% With Elimite in Patients With Active Scabies. (PHASE3)
- Multiple-Site Study to Evaluate the Therapeutic Equivalence of Permethrin Cream, 5% in the Treatment of Scabies (PHASE3)
- A Study to Evaluate the Therapeutic Equivalence of Generic Permethrin Cream 5% to Elimite® in the Treatment of Scabies (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Elimite™ Cream (permethrin) 5% CI brief — competitive landscape report
- Elimite™ Cream (permethrin) 5% updates RSS · CI watch RSS
- Encube Ethicals Pvt. Ltd. portfolio CI